The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
WCLC 2022 | CALGB 140503: sub-lobar resection non-inferior to lobectomy in stage IA node-negative NSCLC
Sanjay Popat, BSc, MBBS, FRCP, PhD, The Royal Marsden NHS Foundation Trust, London, UK, provides an overview of the Phase III CALGB140503 (Alliance) (NCT00499330) study investigating sub-lobar versus lobar resection in patients with non-small cell lung cancer (NSCLC). The primary endpoint was disease-free survival (DFS) and secondary endpoints included overall-survival (OS). The trial demonstrated sub-lobar resection is non-inferior to lobectomy in patients with NSCLC who have pathologically confirmed node-negative disease. DFS and OS were not deteriorated by a lesser surgical intention over lobectomy. This surgical approach spares lung capacity which allows a potentially multimodal approach for patients who require additional treatments in the future. This interview took place at the IASLC 2022 World Conference on Lung Cancer congress in Vienna, Austria.
